Recombinant virus-like particles presenting IL-33 successfully modify the tumor microenvironment and facilitate antitumor immunity in a model of breast cancer-Reference-Cited by-同舟云学术

Recombinant virus-like particles presenting IL-33 successfully modify the tumor microenvironment and facilitate antitumor immunity in a model of breast cancer

Published:2019-12 Issue: Volume:100 Page:316-325
ISSN:1742-7061
Container-title:Acta Biomaterialia
language:en
Short-container-title:Acta Biomaterialia

Author:

Feng Xuejun,Liu Hongxian,Chu Xiaojie,Sun Pengyan,Huang Weiwei,Liu Cunbao,Yang Xu,Sun Wenjia,Bai Hongmei,Ma Yanbing

Funder

CAMS

National Natural Science Foundation of China

Science and Technology Project of Yunnan Province

Fundamental Research Funds for Institute of Pathogen Biology

Publisher

Elsevier BV

Subject

Molecular Biology,Biomedical Engineering,Biochemistry,Biomaterials,General Medicine,Biotechnology

Reference53 articles.

1. Serum interleukin-33 levels in patients with gastric cancer;Sun;Dig. Dis. Sci.,2011

2. High serum levels of the interleukin-33 receptor soluble ST2 as a negative prognostic factor in hepatocellular carcinoma;Bergis;Transl. Oncol.,2013

3. Expression of interleukin-33 is correlated with poor prognosis of patients with squamous cell carcinoma of the tongue;Ishikawa;Auris Nasus Larynx,2014

4. Biliary repair and carcinogenesis are mediated by IL-33-dependent cholangiocyte proliferation;Li;J. Clin. Invest.,2014

5. Serum IL-33 as a diagnostic and prognostic marker in non- small cell lung cancer;Hu;Asian Pac. J. Cancer Prev.,2013

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The quest for nanoparticle-powered vaccines in cancer immunotherapy;Journal of Nanobiotechnology;2024-02-14

2. Virus-like Particle (VLP) Vaccines for Cancer Immunotherapy;International Journal of Molecular Sciences;2023-08-19

3. Nonenveloped Virus-Like Particles: A Promising Antigen-Delivery Strategy for the Induction of Antitumor Immune Responses;Nano LIFE;2022-11-14

4. Recombinant VLPs empower RBM peptides showing no immunogenicity in native SARS-COV-2 protein to elicit a robust neutralizing antibody response;Nanomedicine: Nanotechnology, Biology and Medicine;2022-04

5. Self-assembled peptide and protein nanostructures for anti-cancer therapy: Targeted delivery, stimuli-responsive devices and immunotherapy;Nano Today;2021-06